The Booty Report

News and Updates for Swashbucklers Everywhere

Arrr, the NEJM be singin' of Resmetirom's might in battlin' NASH. Aye, a grand discovery indeed!

2024-02-07

Yarr! Them investigators from th' ongoing MAESTRO-NASH trial be bringin' forth more evidence that resmetirom may be a fine option fer a disease state without any approved remedies. Arr! <i>Medscape Medical News</i>

In a jolly twist of fate, the swashbuckling investigators of the MAESTRO-NASH trial have unveiled their latest treasure: resmetirom, a potential remedy for a disease that has long eluded medical experts. Arrr, this be a momentous discovery indeed!
Ye see, mateys, this resmetirom be like a hidden treasure chest, filled with promise for those afflicted with a disease that has sailed uncharted waters. It be a disease state with no approved treatments, a murky abyss where many have been left to fend for themselves against the relentless onslaught of symptoms.
But fear not, me hearties! These investigators have taken to the high seas, navigating the treacherous waters of science, and have returned with their bounty. They be sayin' that resmetirom may just be the key to unlockin' the prison door that held these poor souls captive for so long.
Now, ye may be wonderin', what be this disease they speak of? Ah, it be none other than NASH, a liver ailment that causes more trouble than a mutinous crew. It be a sneaky scoundrel, slowly destroyin' the liver without showin' any symptoms. A treacherous enemy, indeed!
But let us not despair, me hearties, for resmetirom might just be the cannonball we've been waitin' for to sink this wretched NASH ship. The investigators have shown us evidence, mateys, evidence that this here resmetirom might be a viable option to treat NASH.
So, let us raise our mugs of grog and toast to the brave investigators of the MAESTRO-NASH trial, for they have brought us hope in the form of resmetirom. May their findings be the wind in our sails as we continue the fight against this wretched disease!

Read the Original Article